1. Home
  2. TLS vs NERV Comparison

TLS vs NERV Comparison

Compare TLS & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Telos Corporation

TLS

Telos Corporation

HOLD

Current Price

$4.43

Market Cap

317.1M

Sector

Technology

ML Signal

HOLD

Logo Minerva Neurosciences Inc

NERV

Minerva Neurosciences Inc

HOLD

Current Price

$6.21

Market Cap

301.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TLS
NERV
Founded
1969
2007
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
317.1M
301.6M
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
TLS
NERV
Price
$4.43
$6.21
Analyst Decision
Buy
Buy
Analyst Count
5
2
Target Price
$7.90
$10.50
AVG Volume (30 Days)
421.3K
180.1K
Earning Date
05-11-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
31.51
N/A
EPS
N/A
N/A
Revenue
$164,805,000.00
$41,175,600.00
Revenue This Year
$18.72
N/A
Revenue Next Year
$14.62
N/A
P/E Ratio
N/A
N/A
Revenue Growth
52.21
N/A
52 Week Low
$1.83
$1.30
52 Week High
$8.36
$12.46

Technical Indicators

Market Signals
Indicator
TLS
NERV
Relative Strength Index (RSI) 53.53 48.40
Support Level $3.84 $5.83
Resistance Level $4.61 $6.69
Average True Range (ATR) 0.17 0.51
MACD 0.01 -0.03
Stochastic Oscillator 56.96 22.94

Price Performance

Historical Comparison
TLS
NERV

About TLS Telos Corporation

Telos Corp offers technologically forwarded, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated, and pervasive threats. Its business has two reportable and operating segments namely Security Solutions and Secure Networks. The Security Solutions segment focuses on cybersecurity, cloud, and identity solutions, and the Secure Networks focuses on enterprise security. The company derives maximum revenue from the Security Solutions segment.

About NERV Minerva Neurosciences Inc

Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.

Share on Social Networks: